1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Personalized Medicine and Companion Diagnostic Market - A Strategic Analysis of Industry Trends, Technologies, Participants, and Environment

Cutting-edge new research by KellySciPub indicates that the core personalized medicine market will be worth over $60 billion by 2019. This market is made up of companion diagnostics and targeted therapeutics and is currently worth $42 billion. This market is dominated by oncology, cardiovascular and infectious disease treatment and diagnostics. The report ‘Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market: Strategic Analysis of Industry Trends, Technologies, Participants, and Environment’ has already been procured by 17 of the top 25 Pharma companies globally. In this newly published edition, it is a revolutionary insight into the vertical growing market of personalized healthcare globally.

Individualized, targeted or personalized medicine aims to increase the efficacy of therapeutics via genetic testing and companion diagnostics. Personalized therapeutics and associated companion diagnostics will be more specific and effective thereby giving pharma/biotech companies a significant advantage to recuperate R&D costs. Personalized medicine will reduce the frequency of adverse drug reactions and therefore have a dramatic impact on health economics. Developmental and diagnostic companies will benefit from lower discovery and commercialization costs and more specific market subtypes.

This report describes the current technologies that are propelling the personalized medicine and companion diagnostic market. It examines the current genetic diagnostic tests and companion diagnostic assays that are in use by the medical and pharmaceutical industry today. Current developments in personalized medicine and the pharmacogenomics revolution are discussed. The emerging trends that appear in key markets such as the US, UK, Germany and France are elucidated and analysed. This study reveals market figures of the overall personalized medicine market and also sub-market figures. Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry.

The study also provides a comprehensive financial and product review of key players in the personalized medicine industry. Strategic drivers and restraints of this market are revealed and market opportunities and challenges are identified.

In summary, the personalized medicine and associated companion diagnostic market have huge opportunities for growth. This industry will revolutionize the healthcare system and will improve therapeutic effectiveness and reduce the severity of adverse effects. It has enormous potential for investment and the emergence of genetic-based in vitro diagnostics.

This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by over 317 tables & figures over 279 pages.

The personalized medicine (global & USA) market is presented as follows:

- By Company (e.g., Qiagen, AFFYMETRIX, ATOSSA GENETICS, NODALITY, deCode /Amgen, CELERA, MYRIAD)
- By Geography (US, UK, EU)
- By Segment (Targeted therapeutics, Companion Diagnostics)
- By Sub-market (Companion diagnostic, targeted cancer therapeutic, medical technology, pharmacogenomics, consumer genomics, molecular diagnostics) - By Therapy (Cancer, Cardiovascular, Infectious Disease)

A wealth of financial data & business strategy information is provided including:

- Company financials, sales & revenue figures
- Business Model Strategies for Diagnostic, Pharmaceutical and Biotechnology Companies
- Business Model Strategies for Providers. Provider Systems and Academic Medical Centres
- Business Model Strategies for Payers & Governments
- Private and Public Funding and Personalized Medicine Reimbursement
- Revisions to Current Payment Systems and intellectual property
- How to Gain Market Penetration in the EU
- Cost-effectiveness and Business Value of Personalized Medicine
- Therapeutics and Companion Diagnostics (e.g., BRAC Analysis, Oncotype Dx , KRAS Mutations)
- Comprehensive account of company product portfolios & kits

SWOT, Economic & Regulatory Environment specifics include:

- Key strengths, weaknesses and threats influencing leading player position within the market
- Technologies driving the market (e.g., New-Generation Sequencing Technologies, Ultra-High Throughput Sequencing)
- Top fastest growing market segments and emerging opportunities
- Top pharmaceutical companies within the IPM by market share and revenue
- Comprehensive product portfolios, R&D activity and pipeline therapeutics
- M&A activity and future strategies of top personalized medicine pharmacos
- Personalized Medicine Regulation (USA, UK, Germany, France, Spain, Italy)
- CE-marked Personalized Medicine/Diagnostic Tests
- FDA Advances in Personalized Medicine Regulation

This report highlights a number of significant pharmacos and gives details of their operations, products, financials and business strategy.

- 23andMe
- Affymetrix
- Astex Pharmaceuticals
- Atossa Genetics
- CuraGen
- Celera Corporation (Quest Diagnostics)
- Celldex Therapeutics
- deCode Genetics (Amgen)
- Illumina
- Genelex
- Myriad
- Nodality
-Qiagen

What you will gain:

- An in-depth understanding of the global personalized medicine market and it’s environment
- Current market facts, figures and product lines of key players in the industry
- Emerging trends in key markets such as the US, UK, Germany and France
- Knowledge of how the personalized medicine market will integrate into the global healthcare market
- Technical insights into new generation sequencing technologies and ultra-high throughput sequencing
- Updates on bioinformatics, high throughput systems, genetic analysis kits, companion diagnostics and future technologies
- FDA approved pharmacogenetic tests and recognized biomarkers
- Information on key government and regulatory policies
- Strategies on how to adapt and restructure current business models to this industry


This report tackles key concerns to the personalized medicine market such as:

- Lack of regulatory policy and legislation in the US and Europe
- Reimbursement schemes and payers concerns
- Transition of investigational diagnostic assays and therapeutics to clinical practice
- Direct to consumer (DTC) test kits and implications for the public

Who should read this report?

- Pharmaceutical, biotechnology and diagnostic companies with an interest in personalized medicine
- Industry professionals and business strategists will discover key information to propel their policies
- Investors will gain inside information to dominant players in the industry and future forecasts
- Scientists will get a business perspective and industry insight into how scientific breakthroughs influence the market environment

This report will tell you if the companies mentioned are:
- Strong, competitive players
- Pooling their resources for specific growth and therapeutic areas
- Investing strategically in R&D
- Have a history of strategic M&A activity

This detailed report is supported with 317 figures and tables over 279 pages and profiles the main pharmacos in personalized medicine.

Benefits of Investing in our Cutting-Edge Reports:

Clients receive complementary content* with mid-level and enterprise wide licences
Post-sale complementary consultation with senior expert analyst is included
Use of tables and figures in your own reports and presentations is permitted
Each report provides straight-talking strategic analysis & sector intelligence
All reports are updated each quarter to give you the most up-to-date information

Table Of Contents

Personalized Medicine and Companion Diagnostic Market - A Strategic Analysis of Industry Trends, Technologies, Participants, and Environment
Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market to 2019 - Strategic Analysis of Industry Trends, Technologies, Participants, and Environment
1.0 Executive Summary 11
1.1 Objectives of Report 11
1.2 Scope of Study 12
1.3 Data Sources and Methodology 13
1.4 Key Findings and Observations 13
1.4.1 CYP2C9 and VKORC1 mutations and Warfarin Response 14
1.4.2 KRAS Mutations 14
1.4.3 Herceptin and Breast Cancer 14
1.4.4 BRACAnalysis 14
1.4.5 Oncotype Dx Test 14
1.4.6 Public and Private Funding for Personalized Medical Research 15
1.4.7 New Business Model Required for Personalized Medicine 15
1.4.8 Cost-effectiveness and Business Value of Personalized Medicine 15
1.4.9 Personalized Medicine Market 15
1.4.10 Personalized Medicine Main Industry Players 15
1.4.11 Personalized Medical Care Market 16
1.4.12 Global Personalized Medicine Sub-market Growth 16
2.0 Introduction and Background 17
2.1 Genetics Explained in Five Minutes 17
2.1.1 Why is the Central Dogma of Molecular Biology Important in Personalized Medicine? 18
2.1.2 Genetic Mutations Explained 19
2.1.3 What is the Difference between Genotype and Phenotype? 20
2.1.4 Why do we Need to Look at Genetic Diversity with Respect to Personalized Medicine? 20
2.2 Introduction to Personalized Medicine 22
2.3 Pharmacogenetics 23
2.4 How Personalized Medicine Monitoring can Reduce Adverse Drug Reactions 30
2.5 Pharmacogenetic Study Challenges 31
2.6 Pharmacogenomics 31
2.7 Applications of Pharmacogenomics 32
2.7.1 Pharmacogenomics: Improving the Safety of Medications 32
2.7.1.1 Adverse Drug Reactions 32
2.7.1.2 Pharmacogenomics: Improving the Efficacy of Therapeutics 33
2.7.2 Vioxx Disaster Could have been Prevented with Personalized Medicine 37
2.8 Pharmacogenetic Analysis 37
2.8.1 Single Base Primer Extension 38
2.8.2 Primer Based Base Extension 38
2.8.3 Hybridization Based SNP Analysis 39
2.8.4 Ligation Based Approach 39
2.8.5 New-Generation Sequencing Technologies 40
2.8.6 Ultra-High Throughput Sequencing 41
2.10 Companion Diagnostics 42
2.11 Selected Personalized Medicine Drugs by Biomarker and Indication 49
2.12 Selected Personalized Medicine Test/Kit According to Therapeutic and Indication 59
2.13 Targeted Cancer Therapy 65
2.14 What Percentage of Cancer Patients Could be Treated by Targeted Therapy? 68
3.0 Personalized Medicine Therapeutics and Associated Companion Diagnostics 69
3.1 CYP2C9 and VKORC1 mutations and Warfarin Response 69
3.2 HLA-B*5701 and Abacavir Response 70
3.3 KRAS Mutations 71
3.3.1 Erbitux 72
3.3.2 Vectibix 72
3.4 Herceptin and Breast Cancer 72
3.5 BRACAnalysis 84
3.5.1 Comprehensive BRACAnalysis 87
3.5.2 BRACAnalysis Rearrangement Test (BART) 87
3.5.3 Single Site BRACAnalysis 87
3.5.4 Multisite 3 BRACAnalysis 87
3.6 Oncotype Dx Test 87
3.7 Therascreen EGFR RGQ PCR Kit 87
3.8 Therascreen KRAS RGQ PCR System 88
3.9 Therascreen IDH1/2 test 88
3.10 THxIDâ„¢ -BRAF Kit 88
3.11 Cobas EGFR Mutation Test (Roche) 88
3.12 Prolaris Prostate Cancer Test 89
4.0 Personalized Medicine and Integration into the Healthcare System 90
4.1 The Personalized Medicine Coalition 90
4.2 Personalized Medicine and the Healthcare System 92
4.3 Clinical Application of Personalized Medicine 92
4.4 Clinical Laboratory Improvement Amendments-Certified Laboratory of Genomic Pathology 93
5.0 Private and Public Funding and Personalized Medicine Reimbursement 95
5.1 International Research and Development Personalized Medicine Activity 95
5.1.1 Publically Funded Personalized Medicine Research 95
5.1.2 Privately Funded Personalized Medicine Research 96
5.2 Popular Biological Targets/Pathways in Pharmacogenetic/Pharmacogenomic Research 101
5.3 Equitable Payer Reimbursement 103
5.3.1 Molecular Diagnostic Payments in Personalized Medicine 103
5.3.1.1 RVU-CPT-ICD Coding System 103
5.3.2 Laboratory Service Payments in Personalized Medicine 103
5.3.3 Revisions to Current Payment System 103
5.4 Biorepositories and Biobanks 103
5.5 Intellectual Property and Personalized Medicine 104
6.0 European Personalized Medicine Market - Payments and Investment 105
6.1 Personalized Medicine and The European Market 105
6.2 European Investment in Personalized Medicine 106
6.3 Overview of Reimbursement Policies in Europe 106
6.4 Gaining Market Penetration in the EU 107
6.5 Personalized (Stratified) Medicine Regulation and Reimbursement in the UK 112
6.5.1 Precision Medicine Catapult 117
6.6 CE-marked Personalized Medicine/Diagnostic Tests in the UK 117
6.7 Personalized Medicine Regulation in Germany 118
6.8 Personalized Medicine Regulation in France 119
6.9 Personalized Medicine Regulation in Spain 120
6.10 The Personalized Medicine Regulation in Italy 120
6.11 Challenges of Future Personalized Medicine Development in Europe 120
7.0 Personalized Medicine -Business Model Analysis 122
7.1 New Business Model Required for Personalized Medicine 122
7.2 Business Model Strategies for Diagnostic, Pharmaceutical and Biotechnology Companies 122
7.3 Business Model Strategies for Providers. Provider Systems and Academic Medical Centres 123
7.4 Business Model Strategies for Payers 123
7.5 Business Model Strategies for Governments 124
7.6 Introduction of Non-Health Companies to the Personalized Medicine Market 124
7.7 Change to the Big Pharma Business Model 125
7.8 Cost-effectiveness and Business Value of Personalized Medicine 125
7.9 Comparative Effectiveness Research in Personalized Medicine 126
7.10 Reimbursement, Coverage and Payment Policy 126
8.0 Personalized Medicine Main Industry Players 129
8.1 23andMe 129
8.2 Affymetrix 130
8.3 Astex Pharmaceuticals 132
8.4 Atossa Genetics 134
8.5 CuraGen 135
8.6 Celera Corporation (Quest Diagnostics) 135
8.7 Celldex Therapeutics 136
8.8 deCode Genetics (Amgen) 137
8.9 Illumina 137
8.10 Genelex 139
8.11 Myriad 139
8.12 Nodality 140
8.13 Qiagen 142
8.14 Admera Health (GeneWiz) 144
8.15 Claritas Genomics 144
9.0 Personalized Medicine Industry Products and Kits 146
9.1 23andme 146
9.2 Affymetrix 153
9.3 Astex Pharmaceuticals 154
9.4 Atossa Genetics 155
9.4.1 Mammary Aspirate Specimen Cytology Test (MASCTâ„¢) 155
9.4.2 ForeCYTE Breast Health Test (SM) 155
9.4.3 ArgusCYTE Breast Health Test(SM) 155
9.4.4 FullCYTE Breast Health Test 155
9.4.5 NextCYTE Breast Health Test 155
9.5 Celera (Quest Diagnostics) 156
9.5.1 ViroSeq HIV-1 Genotyping System 156
9.5.2 ViroSeq HIV-1 Integrase Assay 156
9.5.3 ViroSeq HCV Assay 156
9.5.4 ViroSeq HBV Assay 157
9.5.5 Cystic Fibrosis Genotyping Assay 157
9.5.6 LDL-S3GGE Test 157
9.5.7 HDL-S10GGE Test 157
9.5.8 KIF6-StatinCheckTM Genotype Test 158
9.5.9 9p21-EarlyMICheckTM Genotype Test 158
9.5.10 LPA-AspirinCheckTM Genotype Test 158
9.5.11 AlleleSEQR HLA PCR/Sequencing Kits 158
9.5.12 m2000 RealTime PCR System 159
9.5.13 CEGA -16â„¢ Instrument 160
9.6 deCode Genetics 160
9.6.1 deCodeT2 Genetic Test 161
9.6.2 deCODE Breast Cancerâ„¢ 161
9.6.3 deCODE Prostate Cancerâ„¢ 162
9.6.4 deCODE AFâ„¢ 162
9.6.5 deCODE Glaucomaâ„¢ 162
9.6.6 deCODE MIâ„¢ 162
9.6.7 deCODE Completeâ„¢ 163
9.6.8 deCODE Cancerâ„¢ 163
9.6.9 deCODE Cardioâ„¢ 164
9.6.10 deCODE Services 164
9.7 Illumina 165
9.7.1 Illumina HiSeq 2000/1000 166
9.7.2 Genome Analyzer IIx 167
9.7.3 Illumina MiSeq 168
9.7.4 Illumina HiScanHQ 169
9.7.5 Illumina HiScan and iScan Array 169
9.8 Genelex 170
9.8.1 You Scriptâ„¢ 170
9.9 Myriad Genetics 172
9.9.1 BRACAnalysis 172
9.9.2 COLARIS/COLARIS AP 173
9.9.3 MELARIS 174
9.9.4 PANEXIA 174
9.9.5 OnDose 174
9.9.6 PREZEONâ„¢ 174
9.9.7 THERAGUIDE 5FU 174
9.9.8 Prolaris 175
9.10 Nodility 175
9.11 Qiagen 175
9.11.1 Genotyping Products 176
9.11.2 QIAsymphony Platform 178
9.12 Admera Health (GENEWIZ) 180
9.12.1 PGxOne 180
9.12.2 OncoGxOne 182
9.12.3 OncoGxOne Plus 183
9.12.4 FloraCheck 183
9.12.5 EGFR and KRAS Clinical Sequencing 183
9.13 Claritas Genomics 183
9.13.1 ClariFocus Exome for Pediatric Neurology 184
9.13.2 ClariView Array 184
10.0 Personalized Medicine Market Analysis 185
10.1 General Overview 185
10.2 Personalized Medicine Market 185
10.3 Personalized Medical Care Market 186
10.4 Personalized Medicine: Diagnostic and Therapeutic Sub-Market 187
10.4.1 Personalized Medicine Targeted Therapeutics - Oncology 188
10.4.2 Targeted Cancer Therapeutics 189
10.4.3 Top Ten Companies in Oncology Drug Sales 189
10.4.4 Top Five Oncology Drugs 190
10.4.5 Global Oncology Market by Cancer Type 191
10.4.6 Personalized Medicine Oncology Therapeutics Market 192
10.4.7 Personalized Medicine Diagnostic Assays - Oncology 196
10.4.8 Personalized Medicine Cardiovascular Therapeutics Market 199
10.4.9 Personalized Medicine Infectious Disease Therapeutics Market 201
10.4.10 Infectious Disease Diagnostic Assay Market 204
10.5 Global Personalized Medical Technology Market 206
10.6 Global Personalized Medicine Sub-Market Growth 206
10.6.1 PharmacoGenomics/PharmacoGenetics Market Analysis 209
10. 7 Molecular Diagnostics Market 210
10.8 Consumer Genomics Market 210
10.9 Major Player Profit Margin Analysis 211
10.10 Market Participant Analysis 216
10.10.1 23andme 216
10.10.2 Affymetrix 219
10.10.3 Astex Pharmaceuticals 228
10.10.4 Atossa Genetics 230
10.10.5 Celera (Quest Diagnostics) 233
10.10.6 Celldex Therapeutics 238
10.10.7 deCode Genetics (Amgen) 240
10.10.8 Illumina 241
10.10.9 Genelex 244
10.10.10 Myriad 246
10.10.11 Nodality 249
10.10.12 Qiagen 250
10.10.13 bioMerieux 255
11.0 Strengths and Advantages of Personalized Medicine 264
11.1 Sequencing of the Human Genome in 2000 264
11.2 Improving Patient Care and Reducing Side Effects 264
11.3 Personalized Medicine will Reduce Healthcare Costs 264
11.4 FDA Advances in Personalized Medicine Regulation 264
11.5 Advancing Technologies 265
11.5.1 Next Generation Sequencing 265
11.6 Industry Investing in Pharmacogenomics 266
11.7 Consumer Genomics and POC Market 266
11.8 Oncology a Driving Force of Personalized Medicine 267
12.0 Restraints of the Personalized Medicine Market 268
12.1 Lack of Sufficient Regulation 268
12.2 Lack of Sufficient Genotypic Linkage Studies to Disease Phenotype 269
12.3 Reimbursement Issues 269
13.0 Personalized Medicine and Regulatory Policies 271
13.1 Regulation 271
13.2 Genetic Information Non-discrimination Act (GINA) 273
13.3 FDA Advancements on Genetic Testing Approval 274
13.4 FDA- New Models to Assess Gene Therapy Safety 276
13.5 FDA- Companion Diagnostics 276
13.6 FDA - Partnership in Applied Comparative Effectiveness Science (PACES) Initiative 276
13.7 National Institutes of Health Genetic Testing Registry 276
14.0 Final Summary and Future Perspectives 279

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Non-Small Cell Lung Cancer: KOL Insight

Non-Small Cell Lung Cancer: KOL Insight

  • $ 7 495
  • Industry report
  • July 2015
  • by Firstword Pharma

Non-Small Cell Lung Cancer: KOL Insight offers detailed expert opinion on the continuing evolution of the treatment paradigm for EGFR/ALK positive and negative NSCLC, and the potential for targeting ...

Multiple Myeloma Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rising Prevalence, Continued Success of Revlimid and Emerging Supplementary Treatments

Multiple Myeloma Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rising Prevalence, Continued Success of Revlimid and Emerging Supplementary Treatments

  • $ 4 995
  • Industry report
  • July 2015
  • by GBI Research

Multiple Myeloma Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rising Prevalence, Continued Success of Revlimid and Emerging Supplementary Treatments Summary Multiple Myeloma (MM) ...

Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2021 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline

Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2021 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline

  • $ 4 995
  • Industry report
  • July 2015
  • by GBI Research

Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2021 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline Summary Hypertension is a chronic medical condition characterized ...

Therapy Markets In China

July 2015 $ 4 000

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.